Press Release: Instem : Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

PHILADELPHIA--(BUSINESS WIRE)--Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum. The ICH S1B guideline has introduced a WoE approach to assess human carcinogenic potential of small molecule pharmaceuticals and determine whether a 2-year